HealthDay (7/23, Solomon) reports, “Mental health hospitalizations [MHHs] are more common among adults with autism, with more than one-third of all admissions tied to mental health conditions for those with autism, according to a study.” Investigators “found that more than one-third (36 percent) of all admissions for adults with autism in 2019 were MHHs, with schizophrenia the most common reason.” Study results indicate that “among all index MHHs in adults with autism, 17 percent had a 30-day all-cause readmission.” The findings were published in Research in Autism.

Related Links:

— “Mental Health Hospitalizations Common in Adults With Autism,”
Lori Solomon, HealthDay , July 23, 2025

HealthDay (7/22, Thompson ) reports research found that “fewer than one-third of American public schools are screening students for psychological problems, years after the U.S. Surgeon General declared a mental health crisis among the nation’s youth.” Investigators found that “by late 2024, just under 31% of principals surveyed said their school conducts screening for mental health issues.” Furthermore, “about 40% said it was difficult to ensure that students receive appropriate care if kids do speak up about feelings of anxiety or depression, results show.” The findings were published in JAMA Network Open.

Related Links:

— “Few Schools Screen Students For Depression, Anxiety,”
Dennis Thompson , HealthDay , July 22, 2025

NBC News (7/22, Carroll ) reports, “Brain aging may have sped up during the pandemic, even in people who didn’t get sick from Covid, a new study suggests.” By “using brain scans from a very large database, British researchers determined that during the pandemic years of 2021 and 2022, people’s brains showed signs of aging, including shrinkage, according to the report.” Individuals “who got infected with the virus also showed deficits in certain cognitive abilities, such as processing speed and mental flexibility.” The findings were published in Nature Communications.

Psychiatric News (7/22) reports the researchers said, “Our findings provide valuable insight into how the COVID-19 pandemic affected brain health, demonstrating that the general pandemic effects alone, without infection, exerted a substantial detrimental effect on brain health, augmented by bio-social factors (age, health, and social inequalities).”

Related Links:

— “The pandemic aged our brains, whether we got Covid or not, study finds,” Linda Carroll, NBC News, July 22, 2025

Psychiatric News (7/21) reports, “Older patients with treatment-resistant major depressive disorder (MDD) are more likely to be diagnosed with Alzheimer’s disease and other types of dementia than their peers who respond to treatment, according to a study.” But, “compared with older patients who do not have MDD, the risk of dementia is higher for those with MDD regardless of how well their depression responds to treatment.” The findings were published in the American Journal of Geriatric Psychiatry.

Related Links:

— “Dementia Risk in MDD Differs Depending on Treatment Resistance or Responsiveness, Psychiatric News, June 21, 2025

The New York Times (7/21, Barry ) reports, “Over nearly four decades since Prozac [fluoxetine] was approved for the treatment of depression, waves of concern about the effects of antidepressants during pregnancy have resulted in a practical consensus: Though use of the drugs may be associated with a slight rise in the odds of birth defects, the risk of leaving a mother’s depression untreated is often greater.” Now, among a “select group of experts convened by the Food and Drug Administration on Monday to discuss the safety of antidepressants during pregnancy, around half said that women should receive a more clear and forceful warning about potential risks to the fetus.” HHS spokesperson Andrew Nixon “said the agency would not comment on whether there were plans to require a so-called black box warning about the use of selective serotonin reuptake inhibitors, or SSRIs, in pregnancy.”

MedPage Today (7/21, Monaco ) reports, “Women should be better informed about the potential risks of using selective serotonin reuptake inhibitors (SSRIs) during pregnancy, and these risks should be weighed against their benefits, most speakers on an FDA panel selected by Commissioner Marty Makary, MD, MPH, agreed on Monday.” Makary said, “Up to 5% of women in pregnancy are on an antidepressant. Antidepressants like SSRIs can be an effective treatment for depression.” However, “he warned that SSRIs ‘may be unique’ because of their potential interaction with pregnancy.”

NBC News (7/21, Bendix ) also reports.

Related Links:

— The New York Times (requires login and subscription)